Your Global Leader in Stem Cell Market Research
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:
In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies. [Read more…]
March 19, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the Company”), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ transplants. In addition, Veto Cells can durably treat malignant and non-malignant blood diseases through active immune response management. Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. [Read more…]
CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. [Read more…]
On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
